In older postmenopausal women with osteopenia, zoledronate reduced fragility fractures at 6 years

ACP Journal Club16 April 2019In older postmenopausal women with osteopenia, zoledronate reduced fragility fractures at 6 yearsKristine E. Ensrud, MD, MPH, MACP, Carolyn J. Crandall, MD, MS, FACPKristine E. Ensrud, MD, MPH, MACPUniversity of Minnesota and, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA (K.E.E.)Search for more papers by this author, Carolyn J. Crandall, MD, MS, FACPUniversity of California, Los Angeles, California, USA (C.J.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201904160-042 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationReid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379:2407-16. https://pubmed.ncbi.nlm.nih.gov/30575489Clinical Impact RatingsGIM/FP/GP: Endocrinology: Geriatrics: References1 Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. [PMID: 9875874] Google Scholar2 Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. [PMID: 17476007] Google Scholar3 Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28:1729-37. [PMID: 23408697] Google Scholar4 Black DM, Geiger EJ, Li BH, et al. Bisphosphonate use and risk of AFF varies by pre-treatment BMD level: results from the Southern California Osteoporosis Cohort Study (SOCS). J Bone Miner Res. 2018;33(Suppl 1):2 (abstract no. 1007). www.asbmr.org/education/AbstractDetail?aid=94cf315c-de77-4e44-bbf3-acde8c9749fb (accessed 11 Feb 2019). Google Scholar5 Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29:1929-37. [PMID: 24535775] Google Scholar6 Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-39. [PMID: 28492856] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Minnesota and, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA (K.E.E.)University of California, Los Angeles, California, USA (C.J.C.)This article was published at Annals.org on 2 April 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 April 2019Volume 170, Issue 8Page: JC42KeywordsBone mineral densityDrugsHip fracturesNumber needed to treatOdds ratioOsteopeniaOsteoporosisResearch fundingSerious adverse eventsSystemic diseases ePublished: 16 April 2019 Issue Published: 16 April 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...